Rajthanee Hospital vs Fresenius Medical Care AG & Co. KGaA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Rajthanee Hospital Public Company Limited (RJH.BK)

Q3 202620 Aug – 8 Oct 2026

▲4

RJH rides social security growth and fee hopes to strong Q3

Social security patient base beats target early RJH's insured patient count hit 261,000, ahead of its end-2026 goal, with more surgical cases. This boosts patient volume and revenue, supporting profit growth and a DBS buy call with an 18.60 baht target.
Shows a key demand driver that directly lifts RJH's revenue and earnings.
Q2 profit surge stands out in weak hospital sector RJH's Q2 net profit jumped about 80-89% to 113 million baht, far outpacing peers like BDMS and BH. This strong result shows company-specific strength and supports the stock's valuation.
Highlights RJH's exceptional earnings growth versus a sluggish sector, a clear positive for the stock.
Cabinet expands social security coverage, boosting demand The Cabinet approved adding 550,000 insured people in 2026, rising to 1.05 million by 2030. With 53% of RJH's revenue from social security, this expands its patient pool and long-term revenue potential.
A regulatory change that increases RJH's addressable patient base, directly supporting future revenue.
Brokers see SSO fee hike as major profit catalyst The Social Security Office is reviewing per-head payments, with a decision due by Oct 24. A 1% rise could lift RJH's profit by 3.1%, and a 5% rise by 15.3%. Kasikorn and Yuanta see upside, with Kasikorn raising its target to 17.70 baht.
A pending regulatory decision that could significantly boost RJH's profits and has driven recent analyst upgrades.

September 202620 Aug – 8 Oct 2026

▲4

RJH rides social security growth and fee hopes to strong Q3

Social security patient base beats target early RJH's insured patient count hit 261,000, ahead of its end-2026 goal, with more surgical cases. This boosts patient volume and revenue, supporting profit growth and a DBS buy call with an 18.60 baht target.
Shows a key demand driver that directly lifts RJH's revenue and earnings.
Q2 profit surge stands out in weak hospital sector RJH's Q2 net profit jumped about 80-89% to 113 million baht, far outpacing peers like BDMS and BH. This strong result shows company-specific strength and supports the stock's valuation.
Highlights RJH's exceptional earnings growth versus a sluggish sector, a clear positive for the stock.
Cabinet expands social security coverage, boosting demand The Cabinet approved adding 550,000 insured people in 2026, rising to 1.05 million by 2030. With 53% of RJH's revenue from social security, this expands its patient pool and long-term revenue potential.
A regulatory change that increases RJH's addressable patient base, directly supporting future revenue.
Brokers see SSO fee hike as major profit catalyst The Social Security Office is reviewing per-head payments, with a decision due by Oct 24. A 1% rise could lift RJH's profit by 3.1%, and a 5% rise by 15.3%. Kasikorn and Yuanta see upside, with Kasikorn raising its target to 17.70 baht.
A pending regulatory decision that could significantly boost RJH's profits and has driven recent analyst upgrades.

Latest20 Aug – 8 Oct 2026

▲4

RJH rides social security growth and fee hopes to strong Q3

Social security patient base beats target early RJH's insured patient count hit 261,000, ahead of its end-2026 goal, with more surgical cases. This boosts patient volume and revenue, supporting profit growth and a DBS buy call with an 18.60 baht target.
Shows a key demand driver that directly lifts RJH's revenue and earnings.
Q2 profit surge stands out in weak hospital sector RJH's Q2 net profit jumped about 80-89% to 113 million baht, far outpacing peers like BDMS and BH. This strong result shows company-specific strength and supports the stock's valuation.
Highlights RJH's exceptional earnings growth versus a sluggish sector, a clear positive for the stock.
Cabinet expands social security coverage, boosting demand The Cabinet approved adding 550,000 insured people in 2026, rising to 1.05 million by 2030. With 53% of RJH's revenue from social security, this expands its patient pool and long-term revenue potential.
A regulatory change that increases RJH's addressable patient base, directly supporting future revenue.
Brokers see SSO fee hike as major profit catalyst The Social Security Office is reviewing per-head payments, with a decision due by Oct 24. A 1% rise could lift RJH's profit by 3.1%, and a 5% rise by 15.3%. Kasikorn and Yuanta see upside, with Kasikorn raising its target to 17.70 baht.
A pending regulatory decision that could significantly boost RJH's profits and has driven recent analyst upgrades.

Fresenius Medical Care AG & Co. KGaA (FME.XETRA)

Q3 202620 Jul – 7 Oct 2026

▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.
This is the core financial result that directly drives investor confidence and the stock's valuation.
New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.
New products and clinical evidence can open new markets and increase demand for the company's treatments.
China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.
The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.
CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.
A CEO change is a major event that can affect investor sentiment and future strategy.

August 202620 Jul – 7 Oct 2026

▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.
This is the core financial result that directly drives investor confidence and the stock's valuation.
New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.
New products and clinical evidence can open new markets and increase demand for the company's treatments.
China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.
The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.
CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.
A CEO change is a major event that can affect investor sentiment and future strategy.

Latest20 Jul – 7 Oct 2026

▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.
This is the core financial result that directly drives investor confidence and the stock's valuation.
New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.
New products and clinical evidence can open new markets and increase demand for the company's treatments.
China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.
The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.
CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.
A CEO change is a major event that can affect investor sentiment and future strategy.